News >

Durvalumab Success Signifies New Era in Stage III NSCLC

Angelica Welch
Published: Wednesday, Mar 28, 2018

Edward S. Kim, MD

Edward S. Kim, MD
Findings from the phase III PACIFIC trial solidified the benefit of the PD-L1 inhibitor durvalumab (Imfinzi) in the treatment of patients with stage III non–small cell lung cancer (NSCLC), according to Edward S. Kim, MD.

A study of pembrolizumab (Keytruda), paclitaxel, carboplatin, and radiation therapy in patients with stage II-IIIB NSCLC is currently recruiting (NCT02621398). There is also a study of consolidation pembrolizumab following chemoradiation in patients with inoperable/unresectable stage III NSCLC that is ongoing (NCT02343952). Additionally, the NICOLAS study is investigating the combination nivolumab (Opdivo) with standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA-B NSCLC (NCT02434081).
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929 doi: 10.1056/NEJMoa1709937.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication